media – Page 24 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Wegovy oral tablets receive FDA approval, ushering in the “dual-dosage era” for GLP-1 weight-loss drugs

Novo Nordisk dropped a bombshell at the end of 2025. On December 23, the company announced that its daily oral semaglutide tablets (trade name: Wegovy® ) received FDA approval, becoming the world’s first oral GLP-1 receptor agonist for weight management. The product is expected to launch in the US out-of-pocket market in early January 2026, marking a shift in the competition for GLP-1 weight-loss drugs from the injectable era to a “dual-dosage form” era with both oral and injectable options. Image source: Novo Nordisk website Compared to the injectable version, Wegovy tablets have unique requirements regarding administration. Patients must take it daily on an empty stomach, with only a small amount of water, and must not eat, drink, or take other medications for half an hour after taking the medication. This strict administration guideline aims to ensure optimal absorption of the drug in the gastrointestinal tract, but it also places ...
- Source: drugdu
- 68
- December 25, 2025
The leading medical device company’s new venture is aiming for an IPO!

According to recent foreign media reports, Medtronic, the world’s leading medical device company, has entered a critical stage in a major strategic initiative. Medtronic announced that its diabetes business, MiniMed, has filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC). Image source: Latest Medical Device News on MassDevice 01 Stripping and splitting Listed on Nasdaq On May 21 this year, Medtronic officially announced its plan to spin off its diabetes business into a new independent publicly traded company, MiniMed, and made it clear that it would prioritize completing this process through an initial public offering (IPO) and subsequent equity divestiture, with all work expected to be completed within the next 18 months. Recently, with Medtronic’s official announcement, this business divestiture process has made substantial progress. MiniMed plans to list on the Nasdaq Stock Exchange under the ticker symbol “MMED,” aiming to raise no more ...
- Source: drugdu
- 83
- December 25, 2025
Patient dies in Pfizer hemophilia drug trial, company issues statement

On December 23 local time, Pfizer Inc. announced that a patient participating in a long-term study of its hemophilia drug had died following severe side effects. Pfizer’s stock closed down more than 1% on the same day. According to the European Haemophilia Consortium, a patient support organization, the patient died on December 14 from a brain hemorrhage following a stroke. The long-term study involved Pfizer’s long-acting hemophilia therapy, Hympavzi. The drug, administered via weekly injections, was approved in the United States last year for the treatment of patients aged 12 and older with hemophilia A or B. It works by targeting specific clotting proteins to prevent or reduce bleeding episodes. Regarding the fatality, Pfizer responded in a statement: “Pfizer, along with trial investigators and an independent external Data Monitoring Committee, is actively gathering information to better understand the complex and multifactorial circumstances surrounding this event.” The company further stated that, ...
- Source: drugdu
- 71
- December 25, 2025
Sanofi to Acquire Dynavax for $2.2 Billion, Strengthening Vaccine Business Portfolio

French pharmaceutical giant Sanofi announced on Wednesday that it will acquire U.S. vaccine company Dynavax Technologies for approximately $2.2 billion (€1.9 billion) in cash. This deal will grant Sanofi access to an approved hepatitis B vaccine. Following the news, Dynavax’s stock surged nearly 40% in early U.S. trading. This year, Sanofi has completed several acquisitions aimed at reducing its reliance on the blockbuster asthma drug Dupixent and diversifying its business. In July, the company acquired British private biotech firm Vicebio for $1.5 billion, shortly after finalizing its acquisition of U.S. rare disease drugmaker BluePrint Medicines, a deal valued at up to $9.5 billion. Under the terms of the agreement, Sanofi will acquire Dynavax for $15.50 per share in cash, representing a 39% premium over its closing price of $11.13 on Tuesday. Sanofi stated that it expects the acquisition to be completed in the first quarter of 2026, with payment to ...
- Source: drugdu
- 63
- December 25, 2025
KOREA CHEM

Organiser：Kyungyon Exhibition Company, South Korea Time：March 31–April 3, 2026 Address：KINTEX (Korea International Exhibition Center) Exhibition hall：217-59 Kintekseu-ro, Daehwa-dong, Ilsanseo-gu, Goyang-si, Gyeonggi-do, South Korea Product range: Oil and Powder Processing & Chemical Machinery: Dryers, granulators, mixers, concentrators, sterilizers, agitators, reactors, dough mixers, incubators, valves, classifiers, blenders, industrial boilers, separators, washing machines, sterilization equipment, sludge collectors, spray dryers, compressors, filtration systems, heat exchangers, conveyors, mills, evaporators, vibrators, extractors, dehydrators, deodorizers, antifoaming agents, stirrers Engineering Materials & Components: Nickel, fluoropolymers, silicones, epoxy resins, adhesive tapes, Teflon, special/non-ferrous metals, specialty rubbers, titanium, alloys, synthetic resins, environmental control and safety equipment Environmental Control & Safety Equipment: Process safety, explosion-proof equipment, industrial protection, firefighting equipment Power Transmission Systems: Gear reducers, motors, gearboxes, frequency converters, couplings Control Equipment & Systems: Process control, sensors, pressure gauges, thermometers, flow meters, material testing instruments, viscometers Plant Engineering & System Design: Measuring instruments, condensers, feeding devices, dust collectors, filling and ...
- Source: drugdu
- 96
- December 25, 2025
Over $2 billion! Another major deal for a domestically developed innovative drug

Today, Tongyi Pharmaceuticals announced that it has entered into an exclusive licensing agreement with MultiValent for CBP-1018, a peptide-drug conjugate for the treatment of prostate cancer . Under the terms of the agreement, MultiValent will obtain exclusive rights to develop and commercialize CBP-1018 in markets outside of Greater China. Tongyi Pharmaceuticals will receive an upfront payment of US$20 million, a 20% equity stake in MultiValent, and up to approximately US$2 billion in future payments for development, regulatory, and commercial milestones, as well as tiered sales royalties. CBP-1018 is a bispecific peptide drug developed by Yimei Pharmaceuticals based on its proprietary Bi-XDC (bispecific dual-ligand conjugate) platform. It is conjugated with Auristatin-E and targets two proteins highly expressed in prostate cancer cells: PSMA and FRα . In a phase I/II clinical trial involving more than 110 patients with metastatic castration-resistant prostate cancer, intravenous CBP-1018 demonstrated encouraging preliminary safety and efficacy. A median ...
- Source: drugdu
- 74
- December 24, 2025
Good news for middle-aged and elderly men! Taincon has become the first generic version of a compound drug for benign prostatic hyperplasia

Recently, according to information published on the official website of the National Medical Products Administration (NMPA), Shandong Huabo Kaisheng Biotechnology, a wholly-owned subsidiary of Guangdong Taienkang, has received approval for the marketing of finasteride tadalafil capsules (trade name: Aitinglie® ) , successfully becoming the first generic version of this drug in China. The original drug was developed by VERU in the United States and approved there in 2021. This domestic production fills a market gap for compound treatment drugs for benign prostatic hyperplasia in China . The unique feature of finasteride tadalafil capsules lies in the synergistic effect of its dual mechanisms of action . • Finasteride, as a type II 5α-reductase inhibitor, can inhibit benign prostatic hyperplasia at its source by reducing the gland size by lowering dihydrotestosterone levels; • Tadalafil, as a PDE5 inhibitor, quickly relieves urinary difficulties by relaxing smooth muscles. This combination achieves both symptomatic and ...
- Source: drugdu
- 70
- December 24, 2025
BeiGene – Catadegbrutinib Initiates International Multicenter Phase II Clinical Trial for B-Cell Leukemia

On December 23, 2025, BeiGene announced the initiation of a global, multicenter Phase II clinical trial of catadegbrutinib (BTK, PROTAC) for B-cell hematologic malignancies. The trial, designated CTR20254960, is titled “Evaluating BGB-16673, a Bruton’s tyrosine kinase-targeting protein degrader, in a Phase 1/2, open-label, dose-escalation and expansion study for the treatment of patients with B-cell malignancies.” This international, multicenter clinical trial plans to enroll 730 participants. The investigational drug in this clinical trial is catadegbrutinib. The primary endpoint was the major response rate (MRR) in stage II. The domestic lead institution is Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and the principal investigator is Professor Li Jian. https://bydrug.pharmcube.com/news/detail/55a4c0369a540aa555859fb702eea4f7
- Source: drugdu
- 84
- December 24, 2025
IND for Oral Small-Molecule KRAS G12D Inhibitor ABSK141 Approved by NMPA

On the morning of December 24, Abbisko Therapeutics announced on the Hong Kong Stock Exchange that its subsidiary, Shanghai Abbisko Biotechnology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) of China for the Investigational New Drug (IND) application of its oral, highly potent, and selective small-molecule KRAS G12D inhibitor ABSK141. The drug is intended for the treatment of patients with advanced solid tumors harboring the KRAS G12D mutation. Reference：https://finance.eastmoney.com/a/202512243600135972.html
- Source: drugdu
- 68
- December 24, 2025
Wantai Bio’s bivalent HPV vaccine (Escherichia coli) was shortlisted for the National Immunization Program (NIP)

Beijing Business Today — On the evening of December 22, Wantai Bio (603392.SH) announced that its wholly-owned subsidiary, Xiamen Innovax Biotech Co., Ltd., participated in the bidding for the 2025 National Immunization Program (NIP) Vaccine Centralized Procurement Project—specifically for the Bivalent Human Papillomavirus (HPV) Vaccine. The company’s Bivalent HPV Vaccine (E. coli) has been shortlisted with a unit price of 27.5 RMB. Wantai Bio stated that this centralized procurement is organized by the Chinese Center for Disease Control and Prevention (China CDC). If the company subsequently signs the procurement contract and organizes production and supply, it will help expand the sales volume of the shortlisted product, increase its market share, promote domestic market development, and enhance the company’s brand influence. https://finance.eastmoney.com/a/202512223598332095.html
- Source: drugdu
- 63
- December 24, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.